Usefulness of contrast echocardiography in arrhythmogenic right ventricular dysplasia

López‐Fernández, Teresa; Garcı́a-Fernández, Miguel Ángel; David, Esther Pérez; Yangüela, Mar Moreno

doi:10.1016/j.echo.2003.11.013

Cited by 19 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of intravenous TTE contrast has been described in populations with ARVD/C and can improve detection of subtle areas of regional dysfunction (30). Nemes et al (31) recently suggested that abnormalities of RV perfusion can be detected in areas affected by fatty infiltration.…”

Section: Transthoracic Echocardiographymentioning

confidence: 99%

Noninvasive Multimodality Imaging in ARVD/C

Riele

Tandri

Sanborn

et al. 2015

JACC: Cardiovascular Imaging

View full text Add to dashboard Cite

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a familial cardiomyopathy resulting in progressive right ventricular (RV) dysfunction and malignant ventricular arrhythmias. Although ARVD/C is generally considered an inherited cardiomyopathy, the arrhythmogenic nature of the disease is striking. Affected individuals typically present in the second to fourth decade of life with arrhythmias originating from the right ventricle. Over the past decade, pathogenic ARVD/C-causing mutations have been identified in 5 genes encoding the cardiac desmosome. Disruption of the desmosomal connection system between cardiomyocytes may be represented structurally by ventricular enlargement, global or regional contraction abnormalities, RV aneurysms, or fibrofatty replacement. These abnormalities are typically observed in predilection areas, including the subtricuspid region, basal RV free wall, and left ventricular posterolateral wall. As such, structural and functional abnormalities on cardiac imaging constitute an important diagnostic criterion for the disease. This paper discusses the current status and role of echocardiography, cardiac magnetic resonance imaging, and computed tomography for suspected ARVD/C.

show abstract

Section: Transthoracic Echocardiographymentioning

confidence: 99%

Noninvasive Multimodality Imaging in ARVD/C

Riele

Tandri

Sanborn

et al. 2015

JACC: Cardiovascular Imaging

View full text Add to dashboard Cite

show abstract

“…Limitations of echocardiography include the fact that it is subject to obtaining adequate views and that it does not allow for a qualitative evaluation of right-ventricular size and function. Newer echo modalities like three-dimensional echocardiography, strain and tissue Doppler echocardiography may overcome some of these limitations [10,11]. CMR is an attractive imaging method because it is noninvasive and has the unique ability to characterize tissue, specifically by differentiating fat from muscle [12][13][14].…”

Section: Imaging Of the Right Ventriclementioning

confidence: 99%

Arrhythmogenic right-ventricular dysplasia/cardiomyopathy

Calkins

2006

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…Limitations of echocardiography include the fact that it is subject to obtaining adequate views and that it does not allow for a qualitative evaluation of right ventricular size and function. Newer echo modalities, like three-dimensional echocardiography, strain and tissue Doppler echocardiography, may overcome some of these limitations [15,16]. CMR is an attractive imaging method because it is noninvasive and has the unique ability to characterize tissue, specifically by differentiating fat from muscle [17][18][19].…”

Section: Imaging Of the Rvmentioning

confidence: 99%

Arrhythmogenic right ventricular dysplasia/ cardiomyopathy

Prakasa¹,

Calkins

2005

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiomyopathy characterized by ventricular arrhythmias and structural abnormalities of the right ventricle (RV). The most important aspect in the treatment of ARVD/C is establishing a correct diagnosis based on the International Task Force criteria. In our experience, cardiologists are not aware of these diagnostic criteria for ARVD/C and place too much importance on the results of magnetic resonance imaging of the RV. Patients with ARVD/C generally all have an abnormal 12-lead electrocardiogram, abnormal echocardiogram, and ventricular arrhythmias with a left bundle branch block morphology. If noninvasive testing suggests ARVD, invasive testing with an RV angiogram, RV biopsy, and electrophysiology study are recommended. We encourage patients to participate in the National Institutes of Health-sponsored multicenter clinical trial of ARVD/C (http://www.ARVD.comorhttp://www.ARVD.org). Once a diagnosis of ARVD/C is established, the main treatment decision involves whether to implant an implantable cardioverter-defibrillator (ICD). ICDs are recommended for patients who have experienced syncope, sudden death, or a sustained ventricular arrhythmia, and also for patients with overt evidence of ARVD, particularly if the electrophysiology study is abnormal or there is a family history of sudden death. We also recommend treatment of patients with ARVD/C with beta blockers and angiotensin-converting enzyme inhibitors, and that all patients with ARVD/C be screened for a mutation in the gene for plakophilin-2, because this is present in more than one third of patients with ARVD/C and may be helpful in the management of first-degree relatives.

show abstract

Usefulness of contrast echocardiography in arrhythmogenic right ventricular dysplasia

Cited by 19 publications

References 7 publications

Noninvasive Multimodality Imaging in ARVD/C

Noninvasive Multimodality Imaging in ARVD/C

Arrhythmogenic right-ventricular dysplasia/cardiomyopathy

Arrhythmogenic right ventricular dysplasia/ cardiomyopathy

Contact Info

Product

Resources

About